The hepatitis C virus (HCV), which is common among drug users, was first described as non-hepatitis A and non-hepatitis B virus in 1973, until it was finally identified in 1989 by genetic engineering of the hereditary material. In Central Europe, most people are now vaccinated against the hepatitis A virus and the hepatitis B virus, but there is currently no available immunisation against HCV.
Symptoms of hepatitis C include an inflammed liver, pain in the liver and increased production of liver enzymes. There are different treatment options for HCV. The standard treatment option combines interferon with ribavirin. However, this treatment option has no guaranteed success. In addition, the long treatment period of 24 to 72 weeks is unpleasant due to the numerous side effects.
In 1990, the antiviral effect of Ibogaine was reported for the first time. Since then, there have been reports of cures and documented reductions in HCV concentration after Ibogaine treatment. In 2005, Howard Lotsof filed a patent application for the use of Ibogaine and other Iboga alkaloids to treat hepatitis C and related symptoms.
The results of Ibogaine-assisted HCV therapy are promising. Repeated administration of small doses of Ibogaine HCL lowers the viral load slightly but continuously. A single staggered treatment of a high dose of Ibogaine HCl, significantly reduces the viral load of the hepatitis C genotype 3 and is favourably comparable with the interferon-ribavirin therapy. The reduction in viral load continues even after the end of the Ibogaine treatment.
In addition, Ibogaine HCL is significantly less toxic than the conventional therapy. However, within the pharmaceutical industry and many Western doctors, there seems to be no particular interest in alternative methods of treatment. Meanwhile, Ibogaine therapy is far more cost effective than monthly treatment with interferon-ribavirin. Unfortunately, there are no other clinical studies, only anecdotal reports.